NIPA2

Across TCGA pan-cancer cohorts, NIPA2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of NIPA2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where NIPA2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types NIPA2 is over-expressed in tumor, although a few such as LUAD and HNSC show the opposite, repressed pattern.

LUAD, HNSC, and LSCC are the cancer types where NIPA2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NIPA2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	All	−0.656	<.001	6	view →
HNSC	Female	All	−0.150	.035	5	view →
LSCC	All	All	−0.200	.001	3	view →
CCRCC	All	All	+0.361	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

NIPA2–LUAD

Open the LUAD breakdown →